HCV antibody quantitative levels in liver transplant patients: Do they have any relevance in clinical practice?

Ashokkumar Jain, Marilyn Menegus, Ravi Mohanka, Mark Orloff, Peter Abt, Parvez Mantry, Adel Bozorgzadeh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Hepatitis C virus (HCV) is not directly cytopathic to the hepatocytes; however, host immune response against the virus does cause hepatic injury. Production of the HCV antibody is a host immune response to a viral antigen. The currently used HCV antibody assay is a qualitative, not quantitative, assessment. In this study, we sought to quantitatively estimate HCV antibody levels in patients who had undergone liver transplantations at the University of Rochester Medical Center, Rochester, New York, and correlate these levels with HCV RNA viral load, genotype, severity of recurrence, and anti-HCV treatment. Materials and Methods: From 39 liver transplantation patients, we obtained 141 blood samples for quantitative HCV RNA to measure HCV antibody levels quantitatively. Results: Most antibody levels were with in a narrow range with a mean of 32.9 ± 5.1. Samples with undetectable RNA had a mean antibody level of 31.4 ± 8.0, and samples with a positive RNA had mean level of 33.0 ± 4.6. The mean antibody levels were significantly higher for patients with genotype 1 (n = 33) compared with those with genotype 2 (n = 5) (33.2 vs 29.1; P = .007). No correlation was found between antibody levels and severity of hepatic injury with regard to hepatitis activity index or fibrosis score. Six patients with no response to anti-HCV treatment had no change in their mean antibody levels (33.7 vs 34.5). Ten patients who responded to anti-HCV therapy had lower mean levels after therapy, but the changes were not significant (34.2 vs 30.4). Conclusions: Antibody levels in this study did not correlate with viral load or hepatic injury. However, genotype-2 patients had significantly lower levels compared with genotype-1 patients, and patients who responded to anti-HCV therapy demonstrated decreased antibody levels.

Original languageEnglish (US)
Pages (from-to)475-480
Number of pages6
JournalExperimental and Clinical Transplantation
Volume4
Issue number1
StatePublished - Jun 1 2006

Fingerprint

Hepatitis C Antibodies
Hepacivirus
Transplants
Liver
Antibodies
Genotype
RNA
Viral Load
Liver Transplantation
Wounds and Injuries
Therapeutics
Viral Antigens
Hepatitis
Hepatocytes
Fibrosis
Viruses
Recurrence

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Jain, Ashokkumar ; Menegus, Marilyn ; Mohanka, Ravi ; Orloff, Mark ; Abt, Peter ; Mantry, Parvez ; Bozorgzadeh, Adel. / HCV antibody quantitative levels in liver transplant patients : Do they have any relevance in clinical practice?. In: Experimental and Clinical Transplantation. 2006 ; Vol. 4, No. 1. pp. 475-480.
@article{f59de6555a414a0a9072fbd7cb9cb171,
title = "HCV antibody quantitative levels in liver transplant patients: Do they have any relevance in clinical practice?",
abstract = "Objectives: Hepatitis C virus (HCV) is not directly cytopathic to the hepatocytes; however, host immune response against the virus does cause hepatic injury. Production of the HCV antibody is a host immune response to a viral antigen. The currently used HCV antibody assay is a qualitative, not quantitative, assessment. In this study, we sought to quantitatively estimate HCV antibody levels in patients who had undergone liver transplantations at the University of Rochester Medical Center, Rochester, New York, and correlate these levels with HCV RNA viral load, genotype, severity of recurrence, and anti-HCV treatment. Materials and Methods: From 39 liver transplantation patients, we obtained 141 blood samples for quantitative HCV RNA to measure HCV antibody levels quantitatively. Results: Most antibody levels were with in a narrow range with a mean of 32.9 ± 5.1. Samples with undetectable RNA had a mean antibody level of 31.4 ± 8.0, and samples with a positive RNA had mean level of 33.0 ± 4.6. The mean antibody levels were significantly higher for patients with genotype 1 (n = 33) compared with those with genotype 2 (n = 5) (33.2 vs 29.1; P = .007). No correlation was found between antibody levels and severity of hepatic injury with regard to hepatitis activity index or fibrosis score. Six patients with no response to anti-HCV treatment had no change in their mean antibody levels (33.7 vs 34.5). Ten patients who responded to anti-HCV therapy had lower mean levels after therapy, but the changes were not significant (34.2 vs 30.4). Conclusions: Antibody levels in this study did not correlate with viral load or hepatic injury. However, genotype-2 patients had significantly lower levels compared with genotype-1 patients, and patients who responded to anti-HCV therapy demonstrated decreased antibody levels.",
author = "Ashokkumar Jain and Marilyn Menegus and Ravi Mohanka and Mark Orloff and Peter Abt and Parvez Mantry and Adel Bozorgzadeh",
year = "2006",
month = "6",
day = "1",
language = "English (US)",
volume = "4",
pages = "475--480",
journal = "Experimental and Clinical Transplantation",
issn = "1544-1873",
publisher = "Cambridge University Press",
number = "1",

}

Jain, A, Menegus, M, Mohanka, R, Orloff, M, Abt, P, Mantry, P & Bozorgzadeh, A 2006, 'HCV antibody quantitative levels in liver transplant patients: Do they have any relevance in clinical practice?', Experimental and Clinical Transplantation, vol. 4, no. 1, pp. 475-480.

HCV antibody quantitative levels in liver transplant patients : Do they have any relevance in clinical practice? / Jain, Ashokkumar; Menegus, Marilyn; Mohanka, Ravi; Orloff, Mark; Abt, Peter; Mantry, Parvez; Bozorgzadeh, Adel.

In: Experimental and Clinical Transplantation, Vol. 4, No. 1, 01.06.2006, p. 475-480.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HCV antibody quantitative levels in liver transplant patients

T2 - Do they have any relevance in clinical practice?

AU - Jain, Ashokkumar

AU - Menegus, Marilyn

AU - Mohanka, Ravi

AU - Orloff, Mark

AU - Abt, Peter

AU - Mantry, Parvez

AU - Bozorgzadeh, Adel

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Objectives: Hepatitis C virus (HCV) is not directly cytopathic to the hepatocytes; however, host immune response against the virus does cause hepatic injury. Production of the HCV antibody is a host immune response to a viral antigen. The currently used HCV antibody assay is a qualitative, not quantitative, assessment. In this study, we sought to quantitatively estimate HCV antibody levels in patients who had undergone liver transplantations at the University of Rochester Medical Center, Rochester, New York, and correlate these levels with HCV RNA viral load, genotype, severity of recurrence, and anti-HCV treatment. Materials and Methods: From 39 liver transplantation patients, we obtained 141 blood samples for quantitative HCV RNA to measure HCV antibody levels quantitatively. Results: Most antibody levels were with in a narrow range with a mean of 32.9 ± 5.1. Samples with undetectable RNA had a mean antibody level of 31.4 ± 8.0, and samples with a positive RNA had mean level of 33.0 ± 4.6. The mean antibody levels were significantly higher for patients with genotype 1 (n = 33) compared with those with genotype 2 (n = 5) (33.2 vs 29.1; P = .007). No correlation was found between antibody levels and severity of hepatic injury with regard to hepatitis activity index or fibrosis score. Six patients with no response to anti-HCV treatment had no change in their mean antibody levels (33.7 vs 34.5). Ten patients who responded to anti-HCV therapy had lower mean levels after therapy, but the changes were not significant (34.2 vs 30.4). Conclusions: Antibody levels in this study did not correlate with viral load or hepatic injury. However, genotype-2 patients had significantly lower levels compared with genotype-1 patients, and patients who responded to anti-HCV therapy demonstrated decreased antibody levels.

AB - Objectives: Hepatitis C virus (HCV) is not directly cytopathic to the hepatocytes; however, host immune response against the virus does cause hepatic injury. Production of the HCV antibody is a host immune response to a viral antigen. The currently used HCV antibody assay is a qualitative, not quantitative, assessment. In this study, we sought to quantitatively estimate HCV antibody levels in patients who had undergone liver transplantations at the University of Rochester Medical Center, Rochester, New York, and correlate these levels with HCV RNA viral load, genotype, severity of recurrence, and anti-HCV treatment. Materials and Methods: From 39 liver transplantation patients, we obtained 141 blood samples for quantitative HCV RNA to measure HCV antibody levels quantitatively. Results: Most antibody levels were with in a narrow range with a mean of 32.9 ± 5.1. Samples with undetectable RNA had a mean antibody level of 31.4 ± 8.0, and samples with a positive RNA had mean level of 33.0 ± 4.6. The mean antibody levels were significantly higher for patients with genotype 1 (n = 33) compared with those with genotype 2 (n = 5) (33.2 vs 29.1; P = .007). No correlation was found between antibody levels and severity of hepatic injury with regard to hepatitis activity index or fibrosis score. Six patients with no response to anti-HCV treatment had no change in their mean antibody levels (33.7 vs 34.5). Ten patients who responded to anti-HCV therapy had lower mean levels after therapy, but the changes were not significant (34.2 vs 30.4). Conclusions: Antibody levels in this study did not correlate with viral load or hepatic injury. However, genotype-2 patients had significantly lower levels compared with genotype-1 patients, and patients who responded to anti-HCV therapy demonstrated decreased antibody levels.

UR - http://www.scopus.com/inward/record.url?scp=33745621287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745621287&partnerID=8YFLogxK

M3 - Article

C2 - 16827647

AN - SCOPUS:33745621287

VL - 4

SP - 475

EP - 480

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1544-1873

IS - 1

ER -